Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 35

  • 865 clinical trials
  • 357 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis62Systemic lupus erythematosus61Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Sjogren's syndrome29Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis15Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+304

Clinical trials in Musculoskeletal and connective tissue disorders

865 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

865 clinical trials

Diabetic foot+1

Not yet recruiting

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Pirkanmaan hyvinvointialue

Axial spondyloarthritis

Not yet recruiting

A study comparing bimekizumab and adalimumab for treating chest pain in patients with active axial spondyloarthritis who do not respond well to non-steroidal anti-inflammatory drugs.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Rouen

Rheumatoid arthritis

Not yet recruiting

A study to compare two different dosing methods of tocilizumab in patients with rheumatoid arthritis who have low disease activity or are in clinical remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire De Nice

Polymyalgia rheumatica

Not yet recruiting

A study to evaluate the safety and effectiveness of resomelagon in patients with polymyalgia rheumatica who are in remission using glucocorticoids

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Resomelagon
  • Sponsor:Synact Pharma ApS

Axial spondyloarthritis+1

Not yet recruiting

Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Care Arthritis Ltd.

Sjogren's syndrome

Not yet recruiting

A study to evaluate the effect of obinutuzumab on removing specific immune cells in the tissues of patients with Sjögren's syndrome.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Stichting Radboud University Medical Center

Osteoporosis postmenopausal

Not yet recruiting

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Ospedale Galeazzi S.p.A.

Bone sarcoma

Not yet recruiting

Study of regorafenib as maintenance treatment after first-line therapy in patients with bone sarcomas without remaining disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Regorafenib
  • Sponsor:Centre Leon Berard

Systemic scleroderma

Not yet recruiting

Comparing Dapagliflozin and Tocilizumab for Treating Patients with Systemic Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Centrum Medycznego Ksztalcenia Podyplomowego

Psoriatic arthropathy

Not yet recruiting

A Study of Guselkumab and Ciclosporin in Patients with Early Psoriatic Arthritis Transitioning from Skin to Joint Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Fibromyalgia

Not yet recruiting

Study of rituximab for reducing pain in patients with fibromyalgia caused by autoantibodies

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:Region Stockholm – SLSO

Congenital myopathy

Not yet recruiting

Study of ASP2957 Gene Therapy for Male Patients with X-linked Myotubular Myopathy Who Require Breathing Support with Ventilators

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:ASP2957
  • Sponsor:Astellas Gene Therapies Inc.

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate25 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.